Real‑world evidence of imatinib treatment in younger and older patients with chronic myeloid leukaemia: A retrospective single centre analysis
Recent Publication
A study at Krems University Hospital has investigated whether age has an influence on the success of treatment in patients with chronic myeloid leukemia (CML) who have been treated with the tyrosine kinase inhibitor imatinib. The analysis of data from 22 patients over a period of ten years showed that younger and older patients benefit equally from the treatment. There were no relevant differences in remission, disease progression or tolerability.
Graf, R., Kreye, G., Pecherstorfer, M., & Singer, J. (2025). Real‑world evidence of imatinib treatment in younger and older patients with chronic myeloid leukaemia: A retrospective single centre analysis. Oncology Letters, 30(2), 1-7. Article 373. https://doi.org/10.3892/ol.2025.15119
OÄ PD Dr. Gudrun Kreye MBA
Division of Internal Medicine 2 (University Hospital Krems)
Univ.-Prof. Dr. Martin Pecherstorfer
Division of Internal Medicine 2 (University Hospital Krems)
Prim. Clin. Assoc. Prof. PD Dr. Josef Singer MBA PhD
Division of Internal Medicine 2 (University Hospital Krems)